Achievements in Hepatology. Following the 22nd European Gastroenterology Week (October 18–22, 2014)

Yu.M. Stepanov, V.B. Yahmur

Abstract


The article covers recent advances in the management of patients with liver disease of various origin. The use of direct-acting antiviral agents, as well as interferon-free regimens helps to achieve sustained viral response in most patients infected with hepatitis C virus. New data on about the use of statins, proton pump inhibitors, antibiotics in cirrhosis and portal hypertension are shown. A review of entirely new treatment of primary biliary cirrhosis, which is based on stimulation of farnesoid X receptors, was carried out. Clinical trials of alpha-pump, which improves the quality of life in patients with ascitis, as well as a fundamentally new device for extracorporeal detoxification, are presented.


Keywords


antiviral therapy; portal hypertension; liver cirrhosis

References


Recommendations for Testing, Managing, and Treating Hepatitis C. American Association for the Study of Liver Diseases. — 2014. — Мode of access: http://www.hcvguidelines.org

Tarik A. Optimal IFN-free therapy in treatment-naıve patients with HCV genotype 1 infection / A. Tarik, P. Marcellin // Liver Int. — 2015. — № 35 (Suppl. 1). — Р. 56-64.

Asselah T. HCV cirrhosis at the edge of decompensation: Will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment? / T. Asselah, S. Bruno, A. Craxi // Journal of Hepatology. — 2014. — № 61. — Р. 1430-1433.

Honegger J.R. Will There Be a Vaccine to Prevent HCV Infection? / J.R. Honegger, Yan Zhou, С.M. Walker // Semin. Liver Dis. — 2014. — № 34 (1). — Р. 79-88.

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory / L. Swadling, S. Capone, R.D. Antrobus [et al.] // Sci. Transl. Med. — 2014. — № 6. — Р. 261-266.

Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites / M. Mandorfer, S. Bota, Ph. Schwabl [et al.] // Plos one. — 2014. — № 9. — Р. 11. — Мode of access: www.plosone.org/Issue 11/e 110503

Effects of Antimicrobial Prophylaxis and Blood Stream Infections in Patients With Acute Liver Failure: A Retrospective Cohort Study / C.J. Karvellas, J. Cavazos, H. Battenhouse [et al.] // Clin. Gastroenterol. Hepatol. — 2014. — № 2. — Р. 203-210.

New Therapies for Primary Biliary Cirrhosis / A. Floreani, I. Franceschet, L. Perini [et al.] // Clin. Rev. Allergy Immunol. — 2014. — № 21.

Efficacy of Obeticholic Acid in Patients with Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid / G.M. Hirchfield, A. Mason, V. Luketic [et al.] // Gastroentero­logy. — 2014. — № 14. — Р. 530-533.

Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action / R. Poupon // Clin. Res. Hepatol. Gastroenterol. — 2012. — № 36 (1). — S. 3-12.

Bile Acid derivatives as ligands of the farnesoid x receptor: molecular determinants for bile Acid binding and receptor modulation / A. Gioiello, B. Cerra, S. Mostarda [et al.] // Curr. Top. Med. Chem. — 2014. — № 14 (19). — P. 2159-2174.

Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis // Expert Opin. Pharmacother. — 2014. — № 15 (3) — P. 365-72.

Neuschwander-Tetri B.A. Farnesoid x receptor agonists: what they are and how they might be used in treating liver disease / M.G. Silvera, K.D. Lindor // Curr. Gastroenterol. Rep. — 2012. — № 14 (1). — P. 55-62.

Future therapy of portal hypertension in liver cirrhosis — a guess / Tilman Sauerbruch, Jonel Trebicka // Prime Reports. — 2014. — № 6 (95). — Мode of access: http://f1000.com/prime/reports/m/6/95

Bosch J. Hepatic endothelial dysfunction and abnormal angiogenesis: New targets in the treatment of portal hypertension / J. Bosch, J.G. Abraldes, M. Fernаndez, J.C. Garcia-Pagаn // Journal of Hepatology. — 2010. — Vol. 53. — P. 558-567.

Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial / J.S. Abraldes, A. Albillos, R. Banares [et al.] / Gastroenterology. — 2009. — № 136 (5). — Р. 1651-1658.

Management of refractory ascites by the automated low flow pump system (Alfapump) / S. Restellini, P.S. Soares, E. Giostra [et al.] // Rev. Med. Suisse. — 2014. — № 10 (440). — P. 1607-1611.

Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study / P. Bellot, M.W. Welker, G. Soriano [et al.] / J. Hepatol. — 2014. — № 58 (5). — P. 922-927.

Bio-inspired detoxification using 3D-printed hydrogel nanocomposites / G. Maling, Q. Xin, Z.Wei [et al.] // Nature Communicarion. — 2013. — Мode of access: www.nature.com/naturecommunications




DOI: https://doi.org/10.22141/2308-2097.1.55.2015.80375

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru